SCHEDULE 13G/A 0001079973-25-001246 0001999256 XXXXXXXX LIVE 3 Common Stock, par value $0.001 08/11/2025 0001426800 ASSEMBLY BIOSCIENCES, INC. 045396207 Two Tower Place 7th Floor South San Francisco CA 94080 Alexander Schornstein 2M 543523.00 0.00 543523.00 0.00 543523.00 N 3.49 IN ASSEMBLY BIOSCIENCES, INC. Two Tower Place, 7th Floor, South San Francisco, California 94080 Alexander Schornstein Kaiser-Friedrich-Allee 2, 52074 Aachen Germany 004915142314669 Germany Y 543,523 Includes 451,219 shares of Common Stock held by Alexander Schornstein and 92,024 shares of Common Stock held by Camino Capital GmbH, in which Alexander Schornstein is the sole beneficial owner and has sole voting power. This Schedule 13G/A Amendment No. 3 serves to amend the prior Schedule 13G filed with the U.S. Securities and Exchange Commission on August 12, 2025, by Alexander Schornstein under Rule 13d-2(b) (the "Prior Filing"). This amendment addresses certain clerical errors in the Prior Filing, and clarifies that the Prior Filing should be 13G/A Amendment No.2. The Reporting Person's ownership has been updated to include transactions that occurred until the date of this filing. The Reporting Person, as of the day of this filing, no longer owns at least 5% of the Company's outstanding shares, and thus is no longer a beneficial owner. The Reporting Person is no longer required to file additional amendments to Schedule 13G pursuant to Rule 13d-2(d). 3.49% Based upon 15,560,009 shares of common stock of the Issuer issued and outstanding as stated in the Company's registration statement on Form S-3 filed with the United States Securities and Exchange Commission on March 20, 2025, as amended by the registration adding securities to prior Form S-3 on Form S-3MEF filed on August 8, 2025. The offering contemplated in the registration statements was closed on August 11, 2025. 543,523 0 543,523 0 N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Alexander Schornstein /s/ Alexander Schornstein 08/18/2025